ROG
Rogers Corp.

453
Mkt Cap
$1.56B
Volume
0.00
52W High
$114.05
52W Low
$51.43
PE Ratio
-24.48
ROG Fundamentals
50D MA
$81.09
Beta
1.42
Avg. Volume
199,995.67
EPS (Annual)
$1.40
P/B
1.30
Rev/Employee
$259,406.25
Loading...
Loading...
News
all
press releases
Rogers Corporation Announces Transition of Board Chair and Plans to Add New Independent Director
Rogers Corporation (NYSE: ROG) (the Company) today announced that Peter Wallace, Chair of the Board of Directors (the Board), has informed the Board of his decision not to stand for re-election at...
Business Wire·9d ago
News Placeholder
More News
News Placeholder
Rogers Corporation Schedules Third Quarter 2025 Earnings Call for October 29
Rogers Corporation (NYSE:ROG) (Rogers) plans to announce third quarter 2025 results on October 29, 2025 after market close, which will be followed by a conference call at 5:00 pm ET. The call will be...
Business Wire·10d ago
News Placeholder
Roche's Elecsys pTau181 becomes the only FDA-cleared blood test for use in primary care to rule out Alzheimer's-related amyloid pathology
Roche's Elecsys pTau181 becomes the only FDA-cleared blood test for use in primary care to rule out Alzheimer's-related amyloid pathology Roche's Elecsys pTau181 becomes the only FDA-cleared blood...
PR Newswire·12d ago
News Placeholder
Strength Seen in Ouster (OUST): Can Its 13.4% Jump Turn into More Strength?
Ouster (OUST) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Zacks·1mo ago
News Placeholder
Rogers Corp. (ROG) Q2 Earnings Lag Estimates
Rogers Corp. (ROG) delivered earnings and revenue surprises of -32.00% and +2.68%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Sarepta stock falls after Elevidys fails to get backing by EU regulators
Investing.com -- Sarepta Therapeutics Inc. (NASDAQ:SRPT) stock declined 13% Friday after European regulators recommended against approving Elevidys, the company’s gene therapy for Duchenne muscular dystrophy.
investing.com·3mo ago
News Placeholder
TTM (TTMI) Surges 5.4%: Is This an Indication of Further Gains?
TTM (TTMI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Zacks·3mo ago
News Placeholder
European pharmaceutical shares edge lower after Trump threatens 200% drug tariff
Investing.com - Shares of European drugmakers slipped on Wednesday after U.S. President Donald Trump said that tariffs of up to 200% on pharmaceutical imports could be coming "very soon."
investing.com·4mo ago
News Placeholder
Deutsche Bank bearish on European pharma stocks into Q2 amid political headwinds
Investing.com -- Deutsche Bank has made several rating and target price adjustments across the European pharmaceuticals space ahead of second-quarter earnings, flagging continued weakness in the sector and potential opportunities in select names.
investing.com·4mo ago
News Placeholder
Roche shares Fall 2% after fatalities halt Elevidys dosing in key patient group
investing.com·4mo ago

Latest ROG News

View

Advertisement|Remove ads.

Advertisement|Remove ads.